Cargando…

Endotoxins and Non-Alcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. It occurs with a prevalence of up to 25%, of which 10–20% cases progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. The histopathology of NASH is characterized by neutrophilic infil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kessoku, Takaomi, Kobayashi, Takashi, Imajo, Kento, Tanaka, Kosuke, Yamamoto, Atsushi, Takahashi, Kota, Kasai, Yuki, Ozaki, Anna, Iwaki, Michihiro, Nogami, Asako, Honda, Yasushi, Ogawa, Yuji, Kato, Shingo, Higurashi, Takuma, Hosono, Kunihiro, Yoneda, Masato, Okamoto, Takayuki, Usuda, Haruki, Wada, Koichiro, Kobayashi, Noritoshi, Saito, Satoru, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586459/ https://www.ncbi.nlm.nih.gov/pubmed/34777261 http://dx.doi.org/10.3389/fendo.2021.770986

Ejemplares similares

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Efficacy of Bifidobacterium bifidum G9-1 in improving quality of life in patients with chronic constipation: a prospective intervention study
por: FUYUKI, Akiko, et al.
Publicado: (2021)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
por: Ozaki, Anna, et al.
Publicado: (2022)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
por: Nagai, Koki, et al.
Publicado: (2021)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care
por: Tanaka, Kosuke, et al.
Publicado: (2023)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
por: Yamamoto, Atsushi, et al.
Publicado: (2022)

Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
por: Ozaki, Anna, et al.
Publicado: (2021)

Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
por: Yoneda, Masato, et al.
Publicado: (2021)

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
por: Ozaki, Anna, et al.
Publicado: (2019)

Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
por: Tanaka, Kosuke, et al.
Publicado: (2022)

Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility
por: Kato, Shingo, et al.
Publicado: (2019)

Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
por: Yoneda, Masato, et al.
Publicado: (2023)

Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan
por: Kuzuu, Kento, et al.
Publicado: (2021)

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
por: Kobayashi, Takashi, et al.
Publicado: (2023)

A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumours
por: Yoshihara, Tsutomu, et al.
Publicado: (2021)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Prior appendectomy and cerebral infarction as potential risk factors for recurrent ischemic colitis: A retrospective observational study
por: Takatsu, Tomohiro, et al.
Publicado: (2023)

Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
por: Tomeno, Wataru, et al.
Publicado: (2020)

Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers
por: Kato, Takayuki, et al.
Publicado: (2017)

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
por: Hasegawa, Sho, et al.
Publicado: (2021)

A cross-sectional study assessing the relationship between non-alcoholic fatty liver disease and periodontal disease
por: Sato, Satsuki, et al.
Publicado: (2022)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o5qs3c3iplkqlu1mo30r3d2a32